Numab Therapeutics and Ono Pharma Partner To Develop Multi-specific Antibody

Numab Therapeutics AG, an organization creating multi-explicit antibody-based immunotherapies for irritation and cancer disease, and Osaka-settled Research and development situated drug organization, Ono Pharma, both mutually declared a worldwide...

Boehringer's Drug Secures CDSCO Approval For Chronic Kidney Disease

Boehringer Ingelheim's (BI) said its diabetes drug Jardiance (empagliflozin) 10mg measurements structure has now been approved by the Focal Medications Standard Control Association of India for the therapy of ongoing kidney illness (CKD), as an...

Curasight Accelerates Clinical Trials for Five Cancer Indications

Curasight A/S, a clinical development company based in Copenhagen, Denmark, announced that it is accelerating and expanding its clinical treatment strategy by adding new Phase 1/2a trials covering five cancer symptoms

KalVista's Genetic Disease Treatment Triumphs in Late-Stage Study

DelSiTech Ltd., a pharmaceutical development and supply company, and Tolmar International Ltd., a fully integrated pharmaceutical company, have strengthened their partnership by signing a global licensing and development agreement following Tolmar's

Torus Health & Tata 1mg Collaborate for Comprehensive Healthcare

Torus Health has partnered with Tata 1mg to create a unique new solution in the healthcare industry. An innovative initiative by Torus Group, a subsidiary of Cosmea Financial Holdings Pvt Ltd, is about to revolutionize India's health and wellness

IAP's launched Child Health Campaign: 'IAP Ki Baat, Community Ke Saath

The Indian Pediatric Association (IAP) has launched a pioneering program called 'IAP Ki Baat, Community Ke Saath' to engage the community actively and provide valuable information on child health.

Roche & Pathai Expand Digital Pathology for Diagnostics

Roche announced that it has signed an agreement with PathAI, a world leader in artificial intelligence (AI)-based pathology technologies.

Eris Lifesciences Buys 51% in Swiss Parenterals To Expand Sterile Injectables

Eris Lifesciences Ltd., an Indian marked plans organization, reported the extension of its Sterile Injectables impression through the securing of 51% value stake in Swiss Parenterals Ltd. for a thought of Rs.637.50 crore. As per a press...

Anixa Biosciences Initiates Second Ovarian Cancer CAR-T Trial Dosing

Anixa Biosciences, Inc., a clinical technology company focused on treating and preventing cancer, announced that it has started treatment for the fourth patient in its Phase 1 clinical trial of its novel T cell chimeric antigen receptor (CAR-T)

© 2024 India Pharma Outlook. All Rights Reserved.